KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $790.3 million.

  • Biomarin Pharmaceutical's Receivables - Net rose 163.58% to $790.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $790.3 million, marking a year-over-year increase of 163.58%. This contributed to the annual value of $660.5 million for FY2024, which is 423.4% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Receivables - Net stood at $790.3 million, which was up 163.58% from $855.9 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Receivables - Net high stood at $855.9 million for Q2 2025, and its period low was $373.4 million during Q4 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Receivables - Net averaged around $574.3 million, with its median value being $597.9 million (2023).
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 1671.73% in 2021, then surged by 3900.2% in 2023.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Receivables - Net stood at $373.4 million in 2021, then grew by 23.55% to $461.3 million in 2022, then surged by 37.37% to $633.7 million in 2023, then increased by 4.23% to $660.5 million in 2024, then grew by 19.64% to $790.3 million in 2025.
  • Its last three reported values are $790.3 million in Q3 2025, $855.9 million for Q2 2025, and $739.2 million during Q1 2025.